RxDoctor Payments DataLook up a doctor →

David Kudrow, MD

Neurology · Santa Monica, CANPI 1952407488

Payments from drug & device makers

$12,773,083in general payments, 2019–2025

Across 3,771 payments — averaging $3387.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Travere Therapeutics, Inc.$7.4M
  • Jazz Pharmaceuticals Inc.$1.6M
  • Amgen$1.3M
  • Biogen$494K
  • Eli Lilly$490K
  • Biohaven Pharmaceuticals, Inc.$392K
  • plus $1M from 44 others
$295,819in research payments, 2019–2025

Across 70 payments — averaging $4225.98 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$108K
  • Teva Pharmaceuticals USA, Inc.$91K
  • Genentech, Inc.$43K
  • UCB Biosciences Inc.$21K
  • Pfizer$11K
  • Amgen$11K
  • plus $11K from 3 others

What the payments were for

  • Consulting fees$70,42813%
  • Speaking & faculty fees$401,12075%
  • Grants$440%
  • Travel & lodging$39,3027%
  • Food & beverage$20,5264%
  • Education$2030%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,773,083 in reported general payments places this provider in the 95th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$45,340
Medicare patients
65
Services billed
4,322

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Aimovig AutoinjectorErenumab-Aooe87$94,778
Nurtec OdtRimegepant Sulfate33$61,301
Emgality PenGalcanezumab-Gnlm65$44,107
QuliptaAtogepant27$28,840
Emgality SyringeGalcanezumab-Gnlm18$16,635
Sumatriptan Succinate85$15,568
UbrelvyUbrogepant16$15,438
Zolmitriptan22$1,733
Naratriptan Hcl37$1,492
SynthroidLevothyroxine Sodium14$759
RizatriptanRizatriptan Benzoate44$712
Amitriptyline Hcl42$700
Eletriptan HbrEletriptan Hydrobromide13$521
Gabapentin25$391
Topiramate32$312

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$187,611$61,30133 claims
AbbVieQulipta, Ubrelvy, Synthroid$212,205$45,03657 claims
Upsher-smith Laboratories LLCTopiramate$93$31232 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,996 neurology providers in California.

Other neurology in Santa Monica

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →